Skip to main content

Table 1 Characteristics of colorectal cancer patients with CTx therapy

From: miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling

 

All patients

n (%)

Responders

n (%)

Non-responders

n (%)

p-value*

Total number

30

15

15

-

Gender

   

0.7150

 Male

15

7

8

 

 Female

15

8

7

 

Age

   

0.1953

 < 60

7

2

5

 

 ≥ 60

23

13

10

 

Median (range)

67 (44–83)

   

Tumor grade

   

0.3091

 I–II

29

14

15

 

 III-IV

1

1

0

 

Primary tumor site

   

0.6242

 Colon

6

3

2

 

 Rectum

24

12

13